Fusion of hIgG1-Fc to 111In-anti-amyloid single domain antibody fragment VHH-pa2H prolongs blood residential time in APP/PS1 mice but does not increase brain uptake

Nuclear Medicine and Biology

Volumn 42, Issue 8, 2015, Pages 695-702

  Rotman, Maarten ^a   Welling, Mick M ^a   van den Boogaard, Marlinde L ^a   Moursel, Laure Grand ^a   van der Graaf, Linda M ^a   van Buchem, Mark A ^a   van der Maarel, Silvère M ^a   van der Weerd, Louise ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

111In labeling; APPswe PS1dE9 mice; Biodistribution; Fc fusion; SPECT; VHH

Indexed keywords

AMYLOID BETA PROTEIN; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT VHH PA2H ANTIBODY FUSION PROTEIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG; VHH PA2H ANTIBODY; 1-(4-ISOTHIOCYANATOBENZYL)DIETHYLENETRIAMINEPENTAACETIC ACID; AMYLOID PRECURSOR PROTEIN; APP PROTEIN, HUMAN; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G; INDIUM; NANOBODY; PENTETIC ACID; PRESENILIN 1; RADIOPHARMACEUTICAL AGENT;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; BLOOD BRAIN BARRIER; BLOOD SAMPLING; CONJUGATION; CONTROLLED STUDY; DIMERIZATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG RETENTION; DRUG UPTAKE; EMBRYO; HEK293 CELL LINE; HINGE REGION; HUMAN; HUMAN CELL; HUMAN TISSUE; ISOTOPE LABELING; MEAN RESIDENCE TIME; MOUSE; NONHUMAN; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; VALIDATION PROCESS; WILD TYPE; ALZHEIMER DISEASE; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN; C57BL MOUSE; CHEMISTRY; DISEASE MODEL; FLUORESCENT ANTIBODY TECHNIQUE; IMAGE PROCESSING; METABOLIC CLEARANCE RATE; METABOLISM; PHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; SCINTISCANNING; TISSUE DISTRIBUTION; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; DISEASE MODELS, ANIMAL; FLUORESCENT ANTIBODY TECHNIQUE; HEK293 CELLS; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; INDIUM RADIOISOTOPES; ISOTOPE LABELING; METABOLIC CLEARANCE RATE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PENTETIC ACID; POSITRON-EMISSION TOMOGRAPHY; PRESENILIN-1; RADIOPHARMACEUTICALS; SINGLE-DOMAIN ANTIBODIES; TISSUE DISTRIBUTION;

EID: 84931559723     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2015.03.003     Document Type: Article

References (43)

1. Yardehnavi N., Behdani M., Pooshang Bagheri K., Mahmoodzadeh A., Khanahmad H., Shahbazzadeh D., et al. A camelid antibody candidate for development of a therapeutic agent against Hemiscorpius lepturus envenomation. FASEB J 2014, 28:4004-4014.
2. Hmila I., Abdallah R.B.A., Saerens D., Benlasfar Z., Conrath K., Ayeb M.E., et al. VHH, bivalent domains and chimeric heavy chain-only antibodies with high neutralizing efficacy for scorpion toxin AahI'. Mol Immunol 2008, 45:3847-3856.
3. Gad W., Ben-Abderrazek R., Wahni K., Vertommen D., Muyldermans S., Bouhaouala-Zahar B., et al. Wheat germ in vitro translation to produce one of the most toxic sodium channel specific toxins. Biosci Rep 2014, 34:e00122.
4. Cardoso F.M., Ibanez L.I., Van den Hoecke S., De Baets S., Smet A., Roose K., et al. Single-domain antibodies targeting neuraminidase protect against an H5N1 influenza virus challenge. J Virol 2014, 88:8278-8296.
5. Scheuplein F., Rissiek B., Driver J.P., Chen Y.G., Koch-Nolte F., Serreze D.V. A recombinant heavy chain antibody approach blocks ART2 mediated deletion of an iNKT cell population that upon activation inhibits autoimmune diabetes. J Autoimmun 2010, 34:145-154.
6. Impagliazzo A., Tepper A.W., Verrips T.C., Ubbink M., van der Maarel S.M. Structural basis for a PABPN1 aggregation-preventing antibody fragment in OPMD. FEBS Lett 2010, 584:1558-1564.
7. Rutgers K.S., van Remoortere A., van Buchem M.A., Verrips C.T., Greenberg S.M., Bacskai B.J., et al. Differential recognition of vascular and parenchymal beta amyloid deposition. Neurobiol Aging 2011, 32:1774-1783.
8. Rotman M., Welling M.M., Bunschoten A., de Backer M.E., Rip J., Nabuurs R.J., et al. Enhanced glutathione PEGylated liposomal brain delivery of an anti-amyloid single domain antibody fragment in a mouse model for Alzheimer's disease. J Control Release 2015, 203C:40-50.
9. Li T., Bourgeois J.P., Celli S., Glacial F., Le Sourd A.M., Mecheri S., et al. Cell-penetrating anti-GFAP VHH and corresponding fluorescent fusion protein VHH-GFP spontaneously cross the blood-brain barrier and specifically recognize astrocytes: application to brain imaging. FASEB J 2012, 26:3969-3979.
10. Nabuurs R.J.A., Rutgers K.S., Welling M.M., Metaxas A., de Backer M.E., Rotman M., et al. In vivo detection of amyloid-beta deposits using heavy chain antibody fragments in a transgenic mouse model for alzheimer's disease. PLoS One 2012, 7:e38284.
11. Rotman M., Snoeks T.J., van der Weerd L. Pre-clinical optical imaging and MRI for drug development in Alzheimer's disease. Drug Discov Today Technol 2011, 8:e117-e125.
12. Kontermann R.E. Strategies to extend plasma half-lives of recombinant antibodies. BioDrugs 2009, 23:93-109.
13. Kontermann R.E. Strategies for extended serum half-life of protein therapeutics. Curr Opin Biotechnol 2011, 22:868-876.
14. Gunasekaran K., Pentony M., Shen M., Garrett L., Forte C., Woodward A., et al. Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG. J Biol Chem 2010, 285:19637-19646.
15. Martin W.L., West A.P., Gan L., Bjorkman P.J. Crystal structure at 2.8 A of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding. Mol Cell 2001, 7:867-877.
16. Olafsen T., Kenanova V.E., Wu A.M. Tunable pharmacokinetics: modifying the in vivo half-life of antibodies by directed mutagenesis of the Fc fragment. Nat Protoc 2006, 1:2048-2060.
17. Ying T., Ju T.W., Wang Y., Prabakaran P., Dimitrov D.S. Interactions of IgG1 CH2 and CH3 domains with FcRn. Front Immunol 2014, 5:146.
18. Gould L.H., Sui J., Foellmer H., Oliphant T., Wang T., Ledizet M., et al. Protective and therapeutic capacity of human single-chain Fv-Fc fusion proteins against West Nile virus. J Virol 2005, 79:14606-14613.
19. Ono K., Kamihira M., Kuga Y., Matsumoto H., Hotta A., Itoh T., et al. Production of anti-prion scFv-Fc fusion proteins by recombinant animal cells. J Biosci Bioeng 2003, 95:231-238.
20. Kamihira M., Ono K., Esaka K., Nishijima K., Kigaku R., Komatsu H., et al. High-level expression of single-chain Fv-Fc fusion protein in serum and egg white of genetically manipulated chickens by using a retroviral vector. J Virol 2005, 79:10864-10874.
21. Powers D.B., Amersdorfer P., Poul M., Nielsen U.B., Shalaby M.R., Adams G.P., et al. Expression of single-chain Fv-Fc fusions in Pichia pastoris. J Immunol Methods 2001, 251:123-135.
22. Richard G., Meyers A.J., McLean M.D., Arbabi-Ghahroudi M., MacKenzie R., Hall J.C. In vivo neutralization of alpha-cobratoxin with high-affinity llama single-domain antibodies (VHHs) and a VHH-Fc antibody. PLoS One 2013, 8:e69495.
23. De Buck S., Virdi V., De Meyer T., De Wilde K., Piron R., Nolf J., et al. Production of camel-like antibodies in plants. Methods Mol Biol 2012, 911:305-324.
24. De Buck S., Nolf J., De Meyer T., Virdi V., De Wilde K., Van Lerberge E., et al. Fusion of an Fc chain to a VHH boosts the accumulation levels in Arabidopsis seeds. Plant Biotechnol J 2013, 11:1006-1016.
25. Veggiani G., Ossolengo G., Aliprandi M., Cavallaro U., de Marco A. Single-domain antibodies that compete with the natural ligand fibroblast growth factor block the internalization of the fibroblast growth factor receptor 1. Biochem Biophys Res Commun 2011, 408:692-696.
26. Bell A., Wang Z.J., Arbabi-Ghahroudi M., Chang T.A., Durocher Y., Trojahn U., et al. Differential tumor-targeting abilities of three single-domain antibody formats. Cancer Lett 2010, 289:81-90.
27. Farrington G.K., Caram-Salas N., Haqqani A.S., Brunette E., Eldredge J., Pepinsky B., et al. A novel platform for engineering blood-brain barrier-crossing bispecific biologics. FASEB J 2014, 28:4764-4778.
28. Bazl M.R., Rasaee M.J., Foruzandeh M., Rahimpour A., Kiani J., Rahbarizadeh F., et al. Production of chimeric recombinant single domain antibody-green fluorescent fusion protein in Chinese hamster ovary cells. Hybridoma (Larchmt) 2007, 26:1-9.
29. Aliprandi M., Sparacio E., Pivetta F., Ossolengo G., Maestro R., de Marco A. The availability of a recombinant anti-SNAP antibody in VHH format amplifies the application flexibility of SNAP-tagged proteins. J Biomed Biotechnol 2010, 2010:658954.
30. Rutgers K.S., Nabuurs R.J.A., van den Berg S.A.A., Schenk G.J., Rotman M., Verrips C.T., et al. Transmigration of beta amyloid specific heavy chain antibody fragments across the in vitro blood-brain barrier. Neuroscience 2011, 190:37-42.
31. Reiserer R.S., Harrison F.E., Syverud D.C., McDonald M.P. Impaired spatial learning in the APPSwe+PSEN1DeltaE9 bigenic mouse model of Alzheimer's disease. Genes Brain Behav 2007, 6:54-65.
32. Jankowsky J.L., Fadale D.J., Anderson J., Xu G.M., Gonzales V., Jenkins N.A., et al. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet 2004, 13:159-170.
33. Loening A.M., Gambhir S.S. AMIDE: a free software tool for multimodality medical image analysis. Mol Imaging 2003, 2:131-137.
34. Abulrob A., Sprong H., Van Bergen en Henegouwen P., Stanimirovic D. The blood-brain barrier transmigrating single domain antibody: mechanisms of transport and antigenic epitopes in human brain endothelial cells. J Neurochem 2005, 95:1201-1214.
35. Muruganandam A., Tanha J., Narang S., Stanimirovic D. Selection of phage-displayed llama single-domain antibodies that transmigrate across human blood-brain barrier endothelium. FASEB J 2002, 16:240-242.
36. Pardridge W.M., Boado R.J. Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier. Methods Enzymol 2012, 503:269-292.
37. Niewoehner J., Bohrmann B., Collin L., Urich E., Sade H., Maier P., et al. Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle. Neuron 2014, 81:49-60.
38. Warren M.S., Zerangue N., Woodford K., Roberts L.M., Tate E.H., Feng B., et al. Comparative gene expression profiles of ABC transporters in brain microvessel endothelial cells and brain in five species including human. Pharmacol Res 2009, 59:404-413.
39. Wang Y.J., Gao C.Y., Yang M., Liu X.H., Sun Y., Pollard A., et al. Intramuscular delivery of a single chain antibody gene prevents brain Abeta deposition and cognitive impairment in a mouse model of Alzheimer's disease. Brain Behav Immun 2010, 24:1281-1293.
40. Sagare A., Deane R., Bell R.D., Johnson B., Hamm K., Pendu R., et al. Clearance of amyloid-beta by circulating lipoprotein receptors. Nat Med 2007, 13:1029-1031.
41. Weiner H.L., Frenkel D. Immunology and immunotherapy of Alzheimer's disease. Nat Rev Immunol 2006, 6:404-416.
42. Tarzi R.M., Davies K.A., Robson M.G., Fossati-Jimack L., Saito T., Walport M.J., et al. Nephrotoxic nephritis is mediated by Fcgamma receptors on circulating leukocytes and not intrinsic renal cells. Kidney Int 2002, 62:2087-2096.
43. Morais M., Cantante C., Gano L., Santos I., Lourenco S., Santos C., et al. Biodistribution of a (67)Ga-labeled anti-TNF VHH single-domain antibody containing a bacterial albumin-binding domain (Zag). Nucl Med Biol 2014, 41(Suppl.):e44-e48.